US4390528A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tuftsinyl-tuftsin
Assignee: RESEARCH Corp A NOT-FOR-PROFIT CORP OF NY
•
Filing: 1981-11-16
•
Granted: 1983-06-28
•
Expires: 2001-11-16
Abstract
Abstract The compound L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-threonyl-L-lysyl-L-prolyl-L-arginine, its pharmacologically acceptable salts and derivatives, and certain of its optical isomers are useful for stimulating or inhibiting phagocytosis or pincytosis in mammals.
Inventors
- 👤 Victor A. Najjar
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 22:24
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; C07K16/00; C07K16/06; C07K16/065; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
20 words
Therapeutically useful non-antigenic polypeptides selected from the group consisting of: L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 2
Dependent Claim
20 words
Therapeutically useful non-antigenic polypeptides selected from the group consisting of: L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 3
Dependent Claim
8 words
L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 4
Dependent Claim
8 words
L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 5
Dependent Claim
8 words
D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 6
Dependent Claim
8 words
D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 7
Dependent Claim
8 words
D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 8
Dependent Claim
8 words
D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmacologically acceptable salts and derivatives thereof.
Claim 9
Dependent Claim
38 words
Pharmaceutical compositions containing a phagocytotically or pinocytotically stimulating or inhibiting amount of at least on compound selected from the group consisting of L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg, and pharmacologically acceptable salts and derivatives thereof together with a pharmaceutically acceptable excipient.
Claim 10
Dependent Claim
38 words
Pharmaceutical compositions containing a phagocytotically or pinocytotically stimulating or inhibiting amount of at least on compound selected from the group consisting of L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg, and pharmacologically acceptable salts and derivatives thereof together with a pharmaceutically acceptable excipient.
Claim 11
Dependent Claim
16 words
A composition as in claim 5 containing L-Thr-L-Lys-L-Pro-L-arg-L-Thr-L-Lys-L-Pro-L-Arg or a pharmacologically acceptable salt or derivative thereof.
Claim 12
Dependent Claim
16 words
A composition as in claim 5 containing D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg or a pharmacologically acceptable salt or derivative thereof.
Claim 13
Dependent Claim
16 words
A composition as in claim 5 containing D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg or a pharmacologically acceptable salt or derivative thereof.
Claim 14
Independent Claim
52 words
A method of stimulating or inhibiting phagocytosis or pinocytosis in a mammalian patient in need of such stimulation or inhibition which comprises administering to such patient a stimulating or inhibiting amount of at least one compound selected from the group consisting of: L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmaceutically acceptable salts and derivatives thereof.
Claim 15
Independent Claim
52 words
A method of stimulating or inhibiting phagocytosis or pinocytosis in a mammalian patient in need of such stimulation or inhibition which comprises administering to such patient a stimulating or inhibiting amount of at least one compound selected from the group consisting of: L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg, D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg, D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg and pharmaceutically acceptable salts and derivatives thereof.
Claim 16
Dependent Claim
19 words
A method as in claim 9 wherein the compound is L-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-L-Arg or a pharmacologically acceptable salt or derivative thereof.
Claim 17
Dependent Claim
19 words
A method as in claim 9 wherein the compound is D-Thr-L-Lys-L-Pro-D-Arg-D-Thr-L-Lys-L-Pro-D-Arg or a pharmacologically acceptable salt or derivative thereof.
Claim 18
Dependent Claim
19 words
A method as in claim 9 wherein the compound is D-Thr-L-Lys-L-Pro-L-Arg-L-Thr-L-Lys-L-Pro-D-Arg or a pharmacologically acceptable salt or derivative thereof.
References Cited (Backward Citations)
US4353823A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-06-27 | 1986-12-27 | 1987-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-06-27 | 1990-12-27 | 1991-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-06-27 | 1994-12-27 | 1995-06-28 | $7700.00 | Window Closed / Lapsed |